Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
November 03, 2023 16:30 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
November 02, 2023 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
October 26, 2023 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
October 25, 2023 08:00 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics Announces $92 Million Private Placement Financing
October 23, 2023 08:00 ET
|
Aligos Therapeutics
Proceeds expected to fund the following:- NASH (ALG-055009): top line data from Phase 2a study (Q4 2024)- Hepatitis B/CAM-E (ALG-000184): Phase 2 enabling activities (H2 2024)- Funding expected to...
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
October 03, 2023 07:30 ET
|
Aligos Therapeutics
- NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies - This is the second NIH-funding received to advance the development of...
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
September 21, 2023 07:30 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel...
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
August 03, 2023 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to...
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
July 27, 2023 16:05 ET
|
Aligos Therapeutics
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing...
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
July 19, 2023 07:30 ET
|
Aligos Therapeutics
- Phase 1 study conduct complete with preliminary data indicating THR-beta agonist ALG-055009 was well-tolerated with a favorable PK profile and dose responsive changes in relevant biomarkers ...